NSCLC patients have a median progression-free survival (PFS) of 9–13 months when treated with first- and second-generation EGFR-TKIs, and a median PFS of 18.9 months when treated with third-generation EGFR-TKIs[2–4]. Here, EGFR is linked to non-small cell lung carcinoma.